Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine)
Autore:
Fureder, W; Weltermann, A; Chott, A; Gisslinger, H; Valent, P; Jager, U; Geissler, K; Lechner, K;
Indirizzi:
Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, AKH, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 mostaseol, AKH, A-1090 Vienna, Austria Univ Vienna, Dept Clin Pathol, A-1090 Vienna, Austria Univ Vienna ViennaAustria A-1090 pt Clin Pathol, A-1090 Vienna, Austria
Titolo Testata:
WIENER KLINISCHE WOCHENSCHRIFT
fascicolo: 24, volume: 111, anno: 1999,
pagine: 1027 - 1030
SICI:
0043-5325(199912)111:24<1027:TOHCLW>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN-LYMPHOCYTES; SPLENECTOMY; INTERFERON; THERAPY; MECHANISM; REMISSION; TOXICITY; 2-CDA;
Keywords:
hairy cell leukemia; treatment; 2-chlorodeoxyadenosine; interferon;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Fureder, W Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, AKH, Wahringer Gurtel 18-20, A-1090 Vienna, Austria Univ Vienna Wahringer Gurtel 18-20 Vienna Austria A-1090 stria
Citazione:
W. Fureder et al., "Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine)", WIEN KLIN W, 111(24), 1999, pp. 1027-1030

Abstract

Hairy cell leukemia is a rare lymphoproliferative disorder resistant to conventional chemotherapeutic agents. Recently, the purine analogue cladribine (2-chlorodeoxyadenosine, 2-CdA) was introduced for the treatment of this disease. We report on 14 patients with hairy cell leukemia who were treatedwith 2-CdA at our department between 1993 and 1997. The patients received a single cycle of 2-CdA at a dose of 0.07 or 0.09 mg/kg/day by continuous infusion, over a seven-day period. Five patients were previously untreated, while the others had received prior treatment with interferon-alpha (seven patients), interferon-alpha and splenectomy (one patient) or interferon-alpha, splenectomy and pentostatin (one patient). Six patients achieved complete remission, three a good partial response and three partial remission. Two patients did not respond to treatment and one of them died from septicemia in aplasia. Relapse of the disease occurred in two patients. Side effectssuch as fever (WHO grade 2) and/or neutropenia (WHO grade 4) were noted ineight patients. Thus, 2-CdA is an effective treatment of hairy cell leukemia that can induce long lasting remissions in both, previously treated and untreated patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/09/20 alle ore 22:50:50